Background illustration for clinical trials search

Paid Clinical Trials Murfreesboro

Discover 1,239 paid clinical trials in Murfreesboro, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

for
Neovascular Age-related Macular Degeneration, nAMD
Location: Nashville TN, Carmel IN, St Louis MO, Madison MS,
Sponsor: Amgen

Sex: All

Age: 50+

Code: NCT07614776

Phase 3, Recruiting

Post-market Cosmetic Evaluation of Ariessence™ Pure PDGF+ Following Ablative Laser

for
Immediate Post-Treatment Care, Aging Mid-Face, Aging
Location: Nashville TN, Sacramento CA
Sponsor: Lynch Regenerative Medicine

Sex: All

Age: 40 - 70

Code: NCT07718347

Recruiting

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

for
Radiation Retinopathy, Visual Impairment
Location: Nashville TN, Hixson TN, Lexington KY, Atlanta GA,
Sponsor: Jaeb Center for Health Research

Sex: All

Age: 18+

Code: NCT05844982

Phase 3, Recruiting

The Aim of This Study is to Determine if Oocyte Sorting for Group Culture Using an Artificial Intelligence Image Analysis Tool (MagentaTM) Increases the Usable Blastocyst Yield and Subsequent Pregnancy in Patients Undergoing IVF

for
Infertility Primary
Location: Nashville TN, Cincinnati OH, Las Vegas NV
Sponsor: Ovation Fertility

Sex: All

Age: 0+

Code: NCT06521372

Recruiting

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

for
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC),
Location: Nashville TN, Chattanooga TN, Atlanta GA, Cincinnati OH,
Sponsor: Revolution Medicines, Inc.

Sex: All

Age: 18+

Code: NCT05379985

Phase 1, Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

for
B-cell Acute Lymphoblastic Leukemia
Location: Nashville TN, Chicago IL, Madison WI, Buffalo NY,
Sponsor: Cellectis S.A.

Sex: All

Age: 15 - 50

Code: NCT04150497

Phase 1, Phase 2, Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

for
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer,
Location: Nashville TN, Indianapolis IN, Pittsburgh PA,
Sponsor: Revolution Medicines, Inc.

Sex: All

Age: 18+

Code: NCT06128551

Phase 1, Phase 2, Recruiting

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

for
Neutropenia
Location: Woodland TX, Atlanta GA, Memphis TN, Cincinnati OH,
Sponsor: X4 Pharmaceuticals

Sex: All

Age: 12+

Code: NCT06056297

Phase 3, Recruiting

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

for
Cancer, Melanoma Stage III, Melanoma Stage IV,
Location: Nashville TN, Indianapolis IN, Canton OH, Cleveland OH,
Sponsor: Krystal Biotech, Inc.

Sex: All

Age: 18+

Code: NCT05970497

Phase 1, Phase 2, Recruiting

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: The Woodlands TX, Newnan GA, Germantown TN, Edgewood KY,
Sponsor: Loxo Oncology, Inc.

Sex: All

Age: 18+

Code: NCT06588478

Phase 2, Recruiting

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

for
Cancer, Advanced Cancer, Locally Advanced Carcinoma,
Location: Nashville TN, St Louis MO, Fairfax VA, Sarasota FL,
Sponsor: Angiex, Inc.

Sex: All

Age: 18+

Code: NCT06440005

Phase 1, Recruiting

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

for
Renal Cell Carcinoma
Location: Nashville TN, St Louis MO, Cleveland OH, Madison WI,
Sponsor: HiberCell, Inc.

Sex: All

Age: 18+

Code: NCT06234605

Phase 1, Recruiting

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

for
Breast Cancer, Triple Negative Breast Cancer, PD-L1 Negative
Location: Chattanooga TN, Cincinnati OH, Columbus OH,
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT04468061

Phase 2, Recruiting

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

for
Endometrial Cancer, Cervical Cancer, Ovarian Cancer,
Location: Nashville TN, Birmingham AL, Augusta GA, Chicago IL,
Sponsor: SystImmune Inc.

Sex: All

Age: 18+

Code: NCT06293898

Phase 1, Recruiting

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

for
Epidermal Growth Factor, Epidermal Growth Factor Receptor,
Location: Nashville TN, Houston TX, East Brunswick NJ,
Sponsor: EpiBiologics

Sex: All

Age: 18+

Code: NCT07462377

Phase 1, Recruiting

First In Human Study of CX-2051 in Advanced Solid Tumors

for
Solid Tumor, Adult
Location: Denver CO, Nashville TN, Huntersville NC, Fairfax VA,
Sponsor: CytomX Therapeutics

Sex: All

Age: 18+

Code: NCT06265688

Phase 1, Recruiting

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

for
Triple Negative Breast Cancer
Location: Nashville TN, Chicago IL, New York NY, Aurora CO,
Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Sex: All

Age: 18+

Code: NCT06908928

Phase 1, Recruiting

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

for
Ovarian Cancer
Location: Nashville TN, Indianapolis IN, Centerville OH,
Sponsor: Daiichi Sankyo

Sex: Female

Age: 18+

Code: NCT06819007

Phase 3, Recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

for
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic,
Location: Nashville TN, Richmond VA, Saint Augustine FL,
Sponsor: Loxo Oncology, Inc.

Sex: All

Age: 18+

Code: NCT05254743

Phase 3, Recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

for
Metastatic Solid Tumor, Recurrent Solid Tumor,
Location: Denver CO, Nashville TN, Atlanta GA, St Louis MO,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT06465069

Phase 1, Recruiting